CRNX · NASDAQ · Biotechnology

Crinetics Pharmaceuticals

Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.

$84.97
After-hours close+0.11 (+0.13%)
At close$84.86(+0.01%)
DateEstimateReportedSurprise
Nov 2026−$1.20
Aug 2026−$1.18−$1.14+3.4%
Aug 2026−$1.18−$1.14+3.4%
May 2026−$1.22−$1.23−0.8%
Feb 2026−$1.37−$1.29+5.8%

The latest year is open to everyone — the 35 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
May 2019
Mar 2019
Nov 2018
Aug 2018
Jul 2018
Dec 2017
Sep 2017
Jun 2017
Mar 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 5, 2026−$1.20$21.0M
Aug 4, 2026−$1.18−$1.14+3.4%$14.8M$25.1M+69.2%
Aug 3, 2026−$1.18−$1.14+3.4%$14.8M$25.1M+69.2%
May 7, 2026−$1.22−$1.23−0.8%$8.5M$10.7M+26.1%
Feb 26, 2026−$1.37−$1.29+5.8%$4.5M$6.2M+37.2%

The latest year is open to everyone — the 35 quarters behind it read with an account.

Sign in
Nov 6, 2025
Aug 7, 2025
May 8, 2025
Feb 27, 2025
Nov 12, 2024
Aug 8, 2024
May 9, 2024
Feb 28, 2024
Nov 7, 2023
Aug 8, 2023
May 4, 2023
Feb 28, 2023
Nov 14, 2022
Aug 12, 2022
May 12, 2022
Mar 30, 2022
Nov 5, 2021
Aug 10, 2021
May 6, 2021
Mar 30, 2021
Nov 6, 2020
Aug 7, 2020
May 8, 2020
Mar 9, 2020
Nov 12, 2019
Aug 13, 2019
May 13, 2019
Mar 13, 2019
Nov 13, 2018
Aug 30, 2018
Jul 18, 2018
Dec 31, 2017
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017